---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-055368"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:31:47.290290+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Applied DNA provides investor presentation with no new material disclosures

## Summary
- Company filed a presentation for investor use; no financial results or guidance included.
- Presentation emphasizes cell-free enzymatic DNA platform for genetic medicines.
- No specific data on revenue, contracts, or milestones disclosed in the filing.
- Risks highlighted include history of net losses and going concern doubt.

## SEC filing metadata
- accession: 0001104659-24-055368
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465924055368/0001104659-24-055368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465924055368/tm2413220d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-055368
- JSON: https://secwatch.observer/filing/0001104659-24-055368.json
- Plain text: https://secwatch.observer/filing/0001104659-24-055368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.